An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Inclusion Criteria:

• Participants who were on ongoing ocrelizumab treatment on one of the followingparent-studies [Studies MN39159/CONSONANCE (NCT03523858), BN42082/MUSETTE (NCT04544436), BN42083/GAVOTTE (NCT04548999), BN44083/GLOBEAM, MN43978/CONSONANCEExt., WA40404/O'HAND (NCT04035005), MN43964/OLERO (NCT05269004), GN41791/FENTREPID (NCT04544449), BP46016/MINTAKA, CN41144/OCARINA I-SC (NCT03972306), CN42097/OCARINAII-SC (NCT05232825)] at the time of roll-over and who do not have access to theocrelizumab treatment locally.

• The first dose of study treatment in this extension study will be received noearlier than 5 months after the last treatment in the parent study.

• Negative urine pregnancy test within 24 hours to first dose administered on MN45053study treatment in participants of childbearing potential.

Exclusion Criteria:

• Study treatment is commercially marketed in the participant's country for theparticipant specific disease and is reasonably accessible to the participant.

• Study treatment is available via Post Trial Access Program (PTAP) in theparticipant's country and is accessible to the participant.

• Permanent premature discontinuation of study treatment for any reason during theparent study or during the time between last treatment in the parent study and thefirst dose of study treatment in this extension study (if applicable).

• Any condition that, in the opinion of the investigator, would interfere with theinterpretation of participant safety or place the participant at high risk fortreatment-related complications.

• Concurrent participation in any therapeutic clinical trial (other than the parentstudy).

• Immunocompromised state

• Known active malignancy or are being actively monitored for recurrence ofmalignancy.

• Known presence of other neurological disorders.